StopsBleeding™

StopsBleeding™ is an ISO Certified and FDA approved medical device for control of bleeding in both minor and major lacerations. This is a novel molecule that consists of natural plant-based modified amylopectin. StopsBleeding™ promotes coagulation in two ways; it acts as a scaffold and promotes the extrinsic pathway of coagulation and secondly through it's osmotic action which dehydrates the blood thus increases the concentration of coagulation proteins and platelets. StopsBleeding™ is registered with The Pharmacy and Poisons Board in Kenya.

Overview

- StopsBleeding™ is particularly useful in surgical and invasive vascular procedures as an adjunctive or alternate hemostatic agent in the control of bleeding when traditional methods of stopping bleeding (pressure, ligature, heat) is ineffective.
- StopsBleeding™ is modified amylopectin powder, absorbable, non-biological and hypoallergenic, non-toxic thus can be left in the body.
- StopsBleeding™ is particularly effective in control of bleeding when the edges are rough and area of bleeding is broad and should be applied generously.
- StopsBleeding™ is used for liver and spleen injuries, major vascular (venous and arterial) and accelerates body's natural ability to form a clot in traumatic injuries.
- StopsBleeding™ requires compression or applying heavy pressure long enough to see the bleeding has stopped for both minor and major injuries.
- StopsBleeding™ is packed in sterile package which requires NO special storage conditions and can handle extreme temperatures.
- StopsBleeding™ activates both the intrinsic and extrinsic pathways

While control of bleeding from trauma and minor abrasions is the largest use of this product, we want to emphasize that we have completed several preclinical studies with blood thinners and we have been approved for use in patients with blood thinners and coagulopathies. We have a special indication for use in patient with long term deep in-dwelling vascular lines. This would encompass an expansive area of medicine including dialysis access, vascular procedures in the fields of cardiology, radiology and neurology.

With near complete automation, our price is highly affordable compared to the closest hemostatic agent in the market. Combined with its superior technology and affordable price, we hope to introduce this disruptive technology to the entire world, impacting mankind positively. Below is the summary of the pre-clinical study and a link for full study, videos, and press release documents shall be provided.

We have published an animal study that shows a transection of the femoral artery in a pig model; all the animals treated with StopsBleeding™ survived while those animals where standard manual compression was utilized died – no study gets better than this. Several samples have been used locally by several medical practitioners including surgeons and Obstetrician/Gynecologists.

Pig Model:

https://drive.google.com/file/d/0B7fZut0BtEMub2RhSTdHVWdRSzA/view

https://drive.google.com/file/d/0B7fZut0BtEMuNWE0RHViNGpJMUk/view

OBGYN:

https://youtu.be/FSOZLDWpl3Y

Hemostatic Efficacy of Modified Amylopectin Powder in a Lethal Porcine Model of Extremity Arterial Injury

Hemostatic Efficacy of Modified Amylopectin Powder in a Lethal Porcine Model of Extremity Arterial Injury

Annals of Emergency Medicine, Volume 53, Issue 6, Pages 804-810

Michael Kilbourne, Kaspar Keledjian, John R. Hess, Thomas Scalea, Grant V. Bochicchio

STUDY: Hemostatic Efficacy of Modified Amylopectin Powder in a Lethal Porcine Model of Extremity Arterial Injury

Study objective

Rapid hemostasis is crucial in controlling severe extremity hemorrhage. Our objective is to evaluate the hemostatic efficacy of a newly modified amylopectin powder in a model of severe extremity arterial hemorrhage.

Methods

Anesthetized pigs underwent severe, reproducible femoral artery injuries. Animals were randomized (non-blinded) to either modified amylopectin powder (n=10) or standard gauze application (n=6). Each hemostatic agent was applied through a pool of blood with manual compression for 3-minute intervals until hemostasis was achieved. Fluid resuscitation was infused as necessary to reestablish a mean arterial pressure within at least 80% of the pre-injury mean arterial pressure if possible. The primary measured outcome was total blood loss. Secondary endpoints were survival, time to hemostasis, resuscitation mean arterial pressure, and resuscitation volume.

Results

Pretreatment blood losses were similar in both groups. Median (absolute average deviation of the median) post-treatment blood loss was significantly less in the modified amylopectin powder group than in the gauze group, 275 (108) mL versus 1,312 (171) mL. Resuscitation mean arterial pressure at 180 minutes after injury was 68% of pre-injury mean arterial pressure in the modified amylopectin powder group and undetectable in all control animals. Fluid volume required for resuscitation was 1,962 (258) mL in the modified amylopectin powder group and 2,875 (150) mL in the gauze group. Time to hemostasis was 9.0 (2.1) minutes in the modified amylopectin powder group. Hemostasis was not achieved in any animal in the gauze group. Survival was 100% in the modified amylopectin powder group, whereas no animals survived in the gauze group.

Conclusion

Modified amylopectin powder demonstrates the ability to control major vascular bleeding in a lethal arterial injury model during a 3-hour period.



Testimonials

"*Whatever walks through that door, with SB, I am ready*"- **Trauma Surgeon. IRAQ**

"*With SB taking care of bleeding in the field is as easy as ABC*"- **Paramedic, Texas USA**

"*My son Alex was saved from bleeding out after sustaining a deep leg laceration at home. I was lucky I had SB at home*." **– Parent, USA**

"*I am amazed by the way SB took care of bleeding in my tumor bed*" **– Gyneacologist, INDIA**

"*My CT surgeries now require less blood transfusion*" **– Cardiothoracic Surgeon, NIGERIA**

"*I tried SB and it is amazing*" - **Obstetrician/Gynecologist and Fetal Medicine Specialist, KENYA**

"*In this tough economy, I finally have an efficacious and truly affordable topical hemostatic agent for my procedures*" - **Neurosurgeon, NIGERIA**

	PACKAGE SIZE
	StopsBleeding™ 20g Recommended for home use and first aid box
	StopsBleeding™ 60g Recommended for institution use such as hospitals, operating rooms and general us
	StopsBleeding™ 200g Recommended for mass casualty, trauma centers, Universities and military operations

Distributed by:

OAKMED LTD, OAKDOOR OFFICE | The Office Park, Riverside Drive | P.O. Box 14148-00800, Nairobi | T: 254 20 4445361, F: 254 20 4445320, Mobile: +254771482119, +254202612524 | Email: info@oakmed.co.ke